178 related articles for article (PubMed ID: 32311890)
21. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
22. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
23. [C-kit, NPM1 and FLT3 gene mutation patterns and their prognostic significance in 656 Chinese patients with acute myeloid leukemia].
Ding ZX; Shen HJ; Miao JC; Chen SN; Qiu QC; Qi XF; Jin ZM; Wu DP; He J
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):829-34. PubMed ID: 23384905
[TBL] [Abstract][Full Text] [Related]
24. FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1.
Kim M; Kim J; Kim JR; Han E; Park J; Lim J; Kim Y; Han K; Kim HJ; Min WS; Cho B
Mol Biol Rep; 2015 Feb; 42(2):451-6. PubMed ID: 25287662
[TBL] [Abstract][Full Text] [Related]
25. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
26. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
[TBL] [Abstract][Full Text] [Related]
27. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
Lei YC; Chen XJ; Dai YT; Dai B; Wang JY; Li MH; Liu P; Liu H; Wang KK; Jiang L; Chen B
Acta Pharmacol Sin; 2024 Mar; 45(3):633-645. PubMed ID: 38017299
[TBL] [Abstract][Full Text] [Related]
28. The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation.
Tang F; Zhao X; Ruan G; Jiang Q; Jiang H; Xu L; Wang Y; Zhang X; Liu K; Huang X
Hematol Oncol; 2023 Oct; 41(4):733-742. PubMed ID: 37272204
[TBL] [Abstract][Full Text] [Related]
29. Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.
Wang J; Dao FT; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ; Jiang Q; Qin YZ
Hematol Oncol; 2022 Oct; 40(4):724-733. PubMed ID: 35531760
[TBL] [Abstract][Full Text] [Related]
30. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G
Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601
[TBL] [Abstract][Full Text] [Related]
31. [Clinical features and prognostic factors in adult acute myeloid leukemia patients with FLT3-ITD and CEBPA gene co-mutation].
Pei RR; Zhang RH; Yu JF; Jiang ZX; Sun H; Wan DM; Xie XS; Liu YF; Li T; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):297-301. PubMed ID: 32447933
[No Abstract] [Full Text] [Related]
32. [Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Tang SH; Lu Y; Zhang PS; Liu XH; Du XH; Chen D; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Pei RZ; Tang XW
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):552-557. PubMed ID: 30122013
[No Abstract] [Full Text] [Related]
33. Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
Wei H; Liu X; Wang Y; Lin D; Zhou C; Liu B; Qiu S; Gu R; Li Y; Wei S; Gong B; Liu K; Gong X; Liu Y; Zhang G; Fang Q; Zhang J; Jin J; Ma Y; Mi Y; Wang J
Exp Hematol; 2021 Apr; 96():63-72.e3. PubMed ID: 33524443
[TBL] [Abstract][Full Text] [Related]
34. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
35. Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia.
Hornung R; Jurinovic V; Batcha AMN; Bamopoulos SA; Rothenberg-Thurley M; Amler S; Sauerland MC; Berdel WE; Wörmann BJ; Bohlander SK; Braess J; Hiddemann W; Lehmann S; Mareschal S; Spiekermann K; Metzeler KH; Herold T; Boulesteix AL
Sci Rep; 2018 Jul; 8(1):11293. PubMed ID: 30050054
[TBL] [Abstract][Full Text] [Related]
36. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
Khan M; Cortes J; Kadia T; Naqvi K; Brandt M; Pierce S; Patel KP; Borthakur G; Ravandi F; Konopleva M; Kornblau S; Kantarjian H; Bhalla K; DiNardo CD
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933735
[TBL] [Abstract][Full Text] [Related]
37. [Related Factors Affecting Long-term Prognosis of AML Children with Positive RUNX1-RUNX1T1].
Teng GY; Qu WJ; Zhang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1767-1773. PubMed ID: 31839036
[TBL] [Abstract][Full Text] [Related]
38. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of Coexisting Gene with NRAS in Acute Myeloid Leukemia].
Sheng YP; Hua HY; Chao HY; Zhu WY; Wang ZQ; Zhang Y; Zhou Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):351-356. PubMed ID: 35395962
[TBL] [Abstract][Full Text] [Related]
40. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
